AngioDynamics launches long-term study of NanoKnife for prostate cancer [Yahoo! Finance]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Yahoo! Finance
long-term effects of the NanoKnife system for treating unifocal intermediate-risk prostate cancer. The system uses irreversible electroporation (IRE) technology to treat tumours by delivering high-voltage electrical pulses that create tiny pores in cell membranes, leading to controlled cell death without harming surrounding tissues. The study aims to enrol up to 500 patients globally to validate the safety and efficacy of NanoKnife, building on existing single-centre research. It also seeks to assess how the system can reduce or delay the need for more radical interventions, helping preserve patients' quality of life. Research published in the BJU International journal highlights that traditional surgery leads to urinary leakage in 36% of men with prostate cancer and erectile dysfunction in 95%. By avoiding critical structures such as blood vessels and nerves, NanoKnife aims to treat tumours while minimising these effects. The international registry will track patient outcomes
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE [Yahoo! Finance]Yahoo! Finance
- AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® SystemBusiness Wire
- AngioDynamics' NanoKnife System gains CPT codes for prostate and liver treatments [Yahoo! Finance]Yahoo! Finance
- AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and LiverBusiness Wire
- AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
ANGO
Earnings
- 10/3/24 - Miss
ANGO
Sec Filings
- 10/23/24 - Form SC
- 10/10/24 - Form 4
- 10/8/24 - Form 4
- ANGO's page on the SEC website